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CObjective: To investigate the cost-effectiveness of nonpharmacologi-
cal, nonsurgical interventions for the treatment of hip and/or knee
osteoarthritis. Methods: We identified economic evaluations or cost
studies associated with randomized or quasi-randomized controlled
trials that assessed nonpharmacologic, nonsurgical interventions for
the treatment of hip and/or knee osteoarthritis. Medline, Embase,
PubMed, National Health Service Economic Evaluation Database,
CENTRAL, EconLit, andOpenSIGLEwere searched up toOctober 1, 2010.
Study characteristics extracted include study population, health out-
comes, and economic analysis elements. Economic analyses were as-
sessed by using the Quality of Health Economic Studies instrument,
and themethodological quality of the randomized controlled trials was
graded by using an internal validity checklist. All costs were converted
to 2008 US dollars. Results: Ten economic evaluations and one ran-
domized controlled trial reporting health-care costs met our inclusion O
o rep
cine,
ago,
al So
doi:10.1016/j.jval.2011.09.003riteria. Interventions included exercise programs, acupuncture, reha-
ilitation programs, and lifestyle interventions. Six of the 11 studies
xhibited high risks of bias for the cost and/or effect components of
heir cost-effectiveness estimate. Six studies used comparators of un-
nown cost-effectiveness. Four studies reported cost-effectiveness es-
imates lower than $50,000 per quality-adjusted life-year. All studies
valuating exercise interventions found the programs to be cost saving.
onclusions: There is only limited evidence for the cost-effectiveness
f conservative treatments for the management of hip and/or knee
steoarthritis. More high-quality economic evaluations of conservative
nterventions are needed to further inform practice.
eywords: conservative treatment, cost-effectiveness, hip, knee, osteo-
rthritis, systematic review.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hip and knee osteoarthritis (OA) are significant contributors to the
poor health of many older people worldwide [1,2] and are consid-
ered to be themost seriousmusculoskeletal disorders from a pub-
lic health viewpoint [3,4]. Because of the large burden of disease
nd associated costs of treatment, the effective management of
ip and knee OA is a priority of the World Health Organization [1]
and national rheumatology associations [5].
Guidelines for the treatment of hip and knee OA recommend
the use of conservative treatments prior to surgical interventions
[6,7]. A preference for alternatives to pharmacologic treatments
has been reported because of the risk of complications with phar-
macologic treatments [8]. Guidelines for the care and manage-
ment of hip and/or knee OA from the National Institute for Health
and Clinical Excellence (NICE) recommend nonpharmacologic,
nonsurgical interventions as core treatments, including educa-
tion, advice and access to information, aerobic and strengthening
exercise, and weight loss if overweight/obese [6]. The NICE guide-
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adjunctive treatments because of their less well-proven efficacy.
The Osteoarthritis Research International (OARSI) recommenda-
tions for hip and knee OA include all the NICE recommendations
plus acupuncture [7]. Although NICE recommendations incorpo-
rate cost-effectiveness findings into clinical recommendations,
OARSI recommendations do not.
Our study aimed to investigate the cost-effectiveness of non-
pharmacologic, nonsurgical interventions for the treatment of hip
and/or knee OA. To our knowledge, a systematic review of eco-
nomic evaluations of these interventions has not previously been
published.
Methods
We searched electronic databases for economic evaluations or
cost studies associated with randomized or quasi-randomized
controlled trials (RCTs) that assessed nonpharmacologic, nonsur-
gical interventions for the treatment of hip and/or knee OA. We
ort.
Department of Physical Therapy andHumanMovement Sciences,
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2 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 – 1 2defined a quasi-randomized trial as one in which participants
were allocated to groups by a method that was not truly random,
such as allocation by geographic location, birth date, or member
record number. We searched Medline (1950–October 2010), Em-
base (1989–October 2010), National Health Service (NHS) Economic
Evaluation Database (inception–October 2010), PubMed (incep-
tion–October 2010), and the Cochrane Central Register of Con-
trolled Trials (CENTRAL, inception–October 2010). For access to the
“gray” literature, we also searched EconLit (inception–October
2010) and OpenSIGLE (inception–October 2010). For the PubMed,
Medline, and Embase searches, we used recommended search
terms for economic analyses [9-11], and for the Medline, Embase,
nd CENTRAL searches, we included a wildcard for articles men-
ioning “cost” that also met the main search criteria. No language
estrictions were imposed. We also searched the references of all
rticles thatwe considered potentially relevant. The search results
ere reviewed and assessed by the first author (D.P.). A protocol
as prepared but not published prior to commencing the review.
ull details of the search strategies are given in Appendix 1 of the
upplemental Materials at doi: 10.1016/j.jval.2011.09.003.
Data extraction
The first author (D.P.) extracted the following data from the in-
cluded studies, and the second author (M.C.R.) checked them:
study population, country, intervention, comparator, main health
outcomes (mean, 95% confidence interval [CI], P value), length of
follow-up, type of economic analysis, perspective, cost items,
price year, health-related quality-of-life (HRQoL)measures, source
of HRQoLweights, andmethods for addressing uncertainty. To aid
the comparison of study results, we converted all costs to 2008
prices by using the relevant country’s consumer price index and
converted them to US dollars by using purchasing-power-parity
exchange rates [12]. We contacted four authors for additional in-
formation about their studies and all responded, with one provid-
ing numerical data not reported in the article [13]. The main out-
come measure for our review was the incremental cost per
quality-adjusted life-year (QALY).
Incremental cost-effectiveness ratios in terms of cost per QALY
were extracted or calculated from the published data. For stud-
ies that reported mean Short Form-36 (SF-36) (QualityMetric
Health Outcomes Solutions, Lincoln, RI) scores but did not re-
port QALYs, we used the algorithm proposed by Ara and Brazier
[14] to convert the eight mean health dimension scores of the
SF-36 into cohort-level HRQoL weights. A willingness to pay
(WTP) of $50,000 per QALY was used as the threshold indicating
good value for money [15].
Assessment for risk of bias
To investigate any potential bias in the estimation of effective-
ness, two authors (D.P. and J.H.A.) independently assessed the
RCTs for their methodological risk of bias. For details about the
study design of the RCTs, we obtained hard copies of articles re-
ferred to by the economic studies [16-21]. Risk-of-bias assessment
was performed by using the internal validity checklist recom-
mended by the Cochrane Collaboration Back Review Group [22],
which consists of 11 questions assessing selection, performance,
attrition, and detection biases. By using this checklist, van Tulder
et al. [23] demonstrated a relationship between internal validity
nd effect size; studies satisfying fewer than 6 of the checklist’s 11
nternal validity criteria reported effect sizes on average 50%
igher than equivalent estimates reported from RCTs fulfilling six
r more of the criteria [23]. Based on this threshold, studies in-
cluded in our reviewwere classified as having either a “high risk of
bias” (6 items satisfied) or a “low risk of bias” (6 items satisfied).
The internal validity criteria were graded as suggested by van Tul-
der et al. [23], and final scoring was based on consensus.Quality assessment of economic analyses
We graded the included studies by using the Quality of Health
Economic Studies (QHES) instrument that assesses studies for the
appropriateness of theirmethods, the validity and transparency of
their results, and the comprehensiveness of how they are reported
[24]. The QHES is a 16-item scale that uses a dichotomous “yes” or
“no” response for each item. A “yes” is worth a specific number of
points for each item (reflecting its relative importance), and a “no”
is worth zero. For each study, the points are summed to get a total
score that can range from 0  “extremely poor” quality to 100 
“excellent” quality. The QHES has demonstrated good overall con-
struct validity [24,25]. Based on the total score threshold recom-
mended by Ofman et al. [24], the included studies were classified
as either “high” (75 points) or “low” (75 points) quality.
Because instruments for assessing the quality of cost-effec-
tiveness analyses have, in general, been found to have poor inter-
rater reliability [26], we established a protocol for using the QHES
specifically for this review (see Appendix 2 of the Supplemental
Materials at doi: 10.1016/j.jval.2011.09.003). Two authors (D.P. and
M.C.R.) independently assessed the studies by using these guide-
lines, with final scoring based on consensus; if a consensus could
not be reached, a third author (P.H.) mediated.
Results
Our search identified 1287 articles that were potentially relevant,
of which 21—plus another identified from a reference list [27]—
appeared to satisfy our search criteria (Fig. 1). Of these 22 articles,
we excluded 11; the articles and reasons for their exclusion are
reported in Appendix 3 of the Supplemental Materials at doi:
0.1016/j.jval.2011.09.003.
Characteristics of the 11 included studies are reported in Table
1, the key results from cost-utility analyses are reported in Table 2,
nd the internal validity andQHES assessment scores are reported
n Tables 3 and 4, respectively.
Six of the studieswere set in theUnitedKingdom [28-33], two in
the United States [34,35], and one each in Germany [36], the Neth-
erlands [13], and Spain [37] (Table 1). Incremental cost-effective-
ness ratios with QALYs as the unit of health benefit were reported
by six of the studies [13,28,29,31,33,36], and we calculated the
QALYs for two studies by using published data [30,38]. Exercise
interventions were evaluated by three studies [28,31,34], rehabili-
tation programs by three [13,29,32], acupuncture by one [36], and
ifestyle programs by four [30,33,35,37].
Exercise interventions
Each of the three studies evaluating exercise programs found that
the exercise intervention resulted in better health outcomes at
lower cost (i.e., cost saving). The first of these studies evaluated a
class-based exercise program for people with knee OA. A senior
physiotherapist supervised a circuit of exercises that included
stretching, balance training, and strengthening with functional
and isometric exercises in addition to a home-based exercise pro-
gram [19,31]. From the perspective of the United Kingdom’s NHS
and the social services sector, the class-based exercise program
resulted in lower costs and incremental QALY gains relative to
home-based exercise alone (Table 2). Participants also improved
their aggregate locomotor function scores by an average of 2.89
seconds (95% CI 1.82–3.96; P  0.001).
The second study evaluated a yearlong water exercise pro-
gram delivered by qualified swimming instructors [28]. The pro-
gramwas directed at the hip and knee and included exercises to
improve strength, motion, balance, coordination, and cardio-
vascular conditioning [28]. From a societal perspective and rel-
ative to usual care, water-based exercise resulted in lower costs
and incremental QALY gains. Participants in the water exercise
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versities OA index (WOMAC) pain scores by 0.89 (95% CI 0.08–
1.70; P  0.05).
The third study evaluated two programs implemented at two
clinical centers (tested in the same study) consisting of 3 months
of aerobic exercise (a walking program at 50%–70% heart rate re-
serve) and full body resistance training, respectively. From the
perspective of the health funder and relative to three sessions of
health education plus regular contact, both programs resulted in
lower costs and improved disability scores. Incremental improve-
ment in self-reported disability scores for aerobic and resistance
exercise programs were 0.18 (95% CI 0.07–0.29; P  0.001) and 0.16
95% CI 0.05–0.27; P  0.003), respectively [34]. Aerobic exercise
esulted in lower health-care costs and greater health gains than
id resistance exercise. QALYs were not reported, and we were
nable to calculate them from the data available.
Acupuncture
In the single study of acupuncture for patients with hip and/or
kneeOA, the cost-effectiveness ratio favored the intervention. The
treatment involved needle acupuncture with manual stimulation
performed by physicians certified as trained in acupuncture, with
the number of needles and acupuncture points used at the phy-
sician’s discretion [36]. From a societal perspective and relative
to delayed acupuncture (i.e., treatment delayed 3 months), acu-
puncture resulted in higher costs and incremental QALY gains.
The incremental cost per QALY was $25,707 (2008 US dollars),
Fig. 1 – Flowchart of thindicating good value for money. Participants also improvedtheir WOMAC scores by 16.80 points (95% CI 14.02–19.58; P 
.001) after 3 months.
Rehabilitation programs
The three studies evaluating rehabilitation programs produced
conflicting results. The behavioral-graded activity program aimed
at gradually increasing participants’ activity levels via short- and
long-term goal setting and the integration of new activities into
daily life [13,16]. From a societal perspective and relative to phys-
iotherapy as recommended by the Dutch physiotherapy guide-
lines, the program’s lower costs were offset by incremental QALY
losses. No significant differences in the other primary outcomes
were detected.
The two other rehabilitation studies evaluated the ESCAPE-
knee pain rehabilitation program, which included discussions
with patients about topics such as self-management and coping
strategies and an individualized, progressive exercise routine
[29,32]. The first study reported that from the perspectives of so-
ciety and the NHS and social services sector, respectively, the in-
tervention resulted in higher health-care costs and incremental
QALY losses relative to usual care [29]. Nevertheless, the ESCAPE-
knee pain group showed a 12% increase in the number of partici-
pants achieving significant improvements in WOMAC function
scores from baseline (P 0.038). The programwas not cost-effec-
tive when QALYs were the measure of benefit, and this result
held whether the program was delivered individually or in a
group format.
dy selection process.e stuA follow-up study evaluated a shortened ESCAPE-knee pain
Table 1 – Study characteristics.
Intervention,
publication year,
country, type of analysis
Participants and indication for OA Design and interventions Results for primary health outcome
measure(s) and WOMAC index*
Perspective(s), price year, source of
health-related quality-of-life weights;
cost items; time horizon
Exercise
Class-based
exercise [19,31]
2006
United Kingdom
Cost-utility
214 patients with knee OA from primary
and secondary care settings. Met
American College of Rheumatology
Criteria, radiographic evidence of
knee OA
1-y pragmatic design, physiotherapist led
class-based exercise, 12 participants
per 45-min class, 2  week for 8 wk 
home exercise, difficulty increased at 4
and 8 wk vs. home exercise
Locomotor function:
ALF 2.89 (95% CI 1.82–3.96)
P  0.001
NHS and social services sector,
1999/2000, UK general population via
time trade-off method; Intervention
cost, GP home and surgery visits,
district nurse and practice nurse visits,
day hospital visit, day case
attendances, inpatient cost per day,
outpatient attendances, accident and
emergency attendances; 12 mo
Water-based
therapy [28]
2005
United Kingdom
Cost-effectiveness
312 primary care patients (age  60 y)
with hip and knee OA, clinical lower
limb OA, GP confirmation of diagnosis
and treatment
18-mo pragmatic design,
usual care  water-based therapy,
maximum 30 participants per 1-h
class, up to 84 in 12 mo, led by
swimming instructors vs. usual care
WOMAC Pain subscale score:
0.89 (95% CI 0.08–1.7)
P  0.05
Societal, 2002/2003, UK general
population via time trade-off method;
medications, hospital use,
family/community services, aids or
adaptations, allied or complementary
health visits, personal friends or
family costs, loss of productivity; 12
mo
Facility-based
exercise [34]
2000
United States
Cost-effectiveness
439 participants (age  60 y) with knee
OA from primary care and newspaper
advertising. Knee pain most days of
the month, radiographic evidence of
OA, and functional limitations
18-mo 2-center trial, aerobic and
resistance exercise led by trained
exercise leader, 1-h sessions, 3  week
for 3 mo  home program  15 mo vs.
1.5-h education, 1 month for 3 mo,
regular contact by nurse
Self-reported disability:
Aerobic exercise 0.18 (95% CI
0.07–0.29) P  0.001
Resistance exercise 0.16 (95% CI
0.05–0.27) P  0.003
Health-care funder, 1994, NA;
medical consultation, in-center
activities, home visits, telephone
follow-up, medical referral costs,
adverse events; 18 mo
Acupuncture
Acupuncture [36]
2008
Germany
Cost-utility
489 participants with hip and knee OA
(age  40y ). Clinical/radiologic OA of
hip/knee 6- mo duration, pain in 15
of last 30 d
3-mo pragmatic design, acupuncture 10–
15 treatment sessions in 3 mo
performed by physicians vs. delayed
acupuncture treatment delayed 3 mo
WOMAC index: 16.80 (95% CI 14.02–19.58)
P  0.001
Societal, price year not reported
(assumed 2004), UK general population
via standard gamble method;
acupuncture, physician visits, hospital
visits and services (excluding personal
costs), health insurance costs,
medications, lost workdays; 3 mo
Rehabilitation
Behavioral-graded
activity [13]
2007
The Netherlands
Cost-effectiveness
200 participants from physiotherapy
practices and newspaper
advertisements. Clinical hip or knee
OA, American College of
Rheumatology criteria
65 wk, clustered on physiotherapy
practices, behavioral-graded activity 18
30-min sessions in 12 wk, up to seven
booster sessions vs. treatment
according to Dutch physiotherapy
guidelines up to 18 30-min sessions in
12 wk
Pain (visual analogue scale and WOMAC
subscale), function (WOMAC subscale),
and patient global assessment: NS
difference for all outcomes
Societal, 2003, UK general population via
time trade-off method; GP,
physiotherapy, manual therapist
visits, medications, outpatient and
specialist care, X-ray, MRI and CT
scan, hospital admission, hip/knee
replacements, absenteeism paid,
productivity losses, professional home
care, informal care by friends and
family; 65 wk
(continued on next page)
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Table 1 (continued)
Intervention,
publication year,
country, type of analysis
Participants and indication for OA Design and interventions Results for primary health outcome
measure(s) and WOMAC index*
Perspective(s), price year, source of
health-related quality-of-life weights;
cost items; time horizon
ESCAPE-knee pain [29]
2007
United Kingdom
Cost-effectiveness
418 primary care patients (age  50 y)
with mild, moderate, or severe knee
pain for more than 6 mo
6-mo pragmatic design, clustered on
primary care practices,
physiotherapist-led rehabilitation
program for individuals, 1-h 2  week
 6 wk vs. rehabilitation for groups of
eight vs. usual primary care
Difference in percentage of participants
improving 15% from baseline on WOMAC
Function subscale: 12%
P  0.038
NHS and social services sector/societal,
2003/2004, UK general population via
time trade-off method; intervention
costs, hospital inpatient, outpatient
services, radiograph, MRI, ultrasound,
arthroscopy, blood test, orthotist, day
hospital, community-based medical
services, medications, social security
benefits, lost productivity, informal
care; 6 mo
Modified ESCAPE-knee
pain [32]
2009
United Kingdom
Cost-effectiveness
64 people (age  50 y) with chronic knee
pain (consulted a primary care
physician for mild, moderate, or
severe knee pain lasting for more than
6 mo)
12-mo pragmatic design,
physiotherapist-led rehabilitation
program up to ten 1-h sessions 2 
week  5 wk in groups of six with one
booster session at 4 mo vs. usual
physiotherapy up to ten 30- to 45-min
individual sessions, usual clinical
practice
WOMAC index: NS differences for all
subscales
Perspective unspecified, 2005; UK general
population via time trade-off methods;
intervention costs, health-care
utilization (outpatient visit, accident
and emergency, other secondary care,
GP visit, nurse visit, other primary
care, medication); 12 mo
Lifestyle
Patient education
program [30]
1999
United Kingdom
Cost-minimization
170 primary care patients with knee OA,
symptoms of the knee, radiographic
evidence of OA
1 y, clustered on primary care practices,
nurse-led patient education 
conventional management (4 1-h
sessions  4 wk) vs. conventional
management
WOMAC index: NS difference for all
subscales
Societal/NHS/individual, 1996/1997, UK
general population via time trade-off
method; intervention, hospital
inpatient and outpatient services, X-
ray, community medical services,
medications, vitamins/supplements,
wound management products, social
benefits, allied/complementary health;
1 y
Arthritis self-
management
program [33]
2009
United Kingdom
Cost-effectiveness
812 primary care patients (age  50 y)
with hip and/or knee OA and pain
and/or disability
12-mo pragmatic design, six sessions of
arthritis self-help management plus
education booklet vs. education
booklet alone
SF-36 physical and mental health summary
scores, NS differences
NHS and social services sector/societal;
2002–2003 rates; UK general
population via time trade-off method;
income, health and social care
resources (drugs, hospital, and
community-based health and social
care); personal and family and friends
costs (out-of-pocket expenses, lost
pay, and informal care); indirect
impacts (time off work for participants
and carers); and social security
benefits; 12 mo
(continued on next page)
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Table 1 (continued)
Intervention,
publication year,
country, type of analysis
Participants and indication for OA Design and interventions Results for primary health outcome
measure(s) and WOMAC index*
Perspective(s), price year, source of
health-related quality-of-life weights;
cost items; time horizon
Exercise and diet
program [35]
2009
United States
Cost-effectiveness
316 participants from primary care and
newspaper advertising, knee OA (age
 60 y), BMI  28 kg/m2. Knee pain
most days of the month, sedentary
lifestyle, radiographic knee OA, and
functional limitations due to knee
pain
18-mo efficacy trial, Exercise: aerobic and
resistance, facility-based; 1-h, 3 
week  4 mo, then given the option to
exercise at home with telephone
contact; Diet: encouraged to lose 5%
baseline weight, maintain loss  18
mo, included home visit and group
meetings; Exercise and diet:
combination of the programs; Healthy
lifestyle control: monthly 1-h
educational meetings  3 mo, regular
contact
WOMAC index percentage improvement:
Exercise and diet vs. healthy lifestyle
control
Pain subscale 30.3% (P  0.05)
Function subscale 24.3% (P  0.01)
Stiffness subscale NS
Health-care funder; 2000 dollars; NA;
intervention costs (staff time,
facilities, equipment, and materials),
physician office visits, overnight
hospitalizations; 18 mo
Therapeutic education
and functional
readaptation
program [37]
2006
Spain
Cost outcomes
100 patients attending hospital
outpatient clinic with knee OA, met
Kellgren and Lawrence criteria, on
waiting list for knee replacement 6
mo
9-mo trial, 3-mo program: two 30-min
individual visits including education,
exercise instruction, pain medication
and two 1.5-h group visits vs. two GP
visits and pain medication
WOMAC index:
Pain and Stiffness subscales NS
Function subscale 5.63 (95% CI 0.48–10.78)
P  0.035
Perspective unspecified, GP visits only,
price year not reported (assumed
2001); 9 mo
ALF, aggregate locomotor function; CT, computerized tomography; GP, general practitioner; MRI,magnetic resonance imaging; NHS, National Health Service; NA, not applicable; NS, not significant;
OA, osteoarthritis; WOMAC, Western-Ontario and McMaster Universities osteoarthritis index.
* Positive values represent a beneficial difference.
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make it more clinically applicable and to promote long-term ad-
herence to exercise [32]. Relative to usual physiotherapy, themod-
ified ESCAPE-knee pain program was cost saving (perspective un-
specified). The QALY gains and improvements in the WOMAC
subscale scores were not statistically significant.
Lifestyle programs
None of the four studies evaluating lifestyle programs was cost-
effective when QALYs were the measure of benefit [30,33,35,37].
The cost-effectiveness results, however, were contradictory when
other measures of benefit such asWOMAC scores were employed.
The first study evaluated a patient-education program led by
nurses that sought to inform patients about OA pain prevention,
exercise, joint protection, diet, and relaxation techniques [30].
From the perspectives of society and relative to usual care, the
education program’s significantly higher costs and incremental
Table 2 – Key results of cost-utility analyses.
Program Mean QALY
per person
Mean total cos
per person*
Exercises
Class-based exercise [19,31] 0.045 $769
vs. home-based program 0.022 $779
Water-based therapy [28] 0.022‡ $796
vs. usual care $1,062
Facility-based NA $467
aerobic exercise [34]
vs. resistance exercise NA $470
vs. education NA $497
Acupuncture [36] 0.024‡ $702
vs. delayed acupuncture $71
Rehabilitation
Behavioral-graded activity [13] 0.71 $3,103
vs. physiotherapy guidelines 0.73 $4,097
ESCAPE-knee pain 0.0057 $573
rehabilitation [29]
vs. individual rehabilitation 0.0034 $679
vs. group rehabilitation 0.0009 $454
vs. usual care 0.0096 $272
Modified ESCAPE-knee pain [32] 0.45¶ $517
vs. physiotherapy 0.36¶ $941
Lifestyle programs
Nurse-led patient-education
program [30]
0.011¶ $659
vs. usual care 0.012¶ $209
Diet and exercise [35] NA $6,704
vs. diet only NA $3,523
vs. exercise only NA $3,348
vs. healthy lifestyle NA $697
Six-session arthritis self-management
program [33]
0.01‡ $461/2427
vs. education booklet $289/2503
Therapeutic education and functional
readaptation [37]
0.011¶ $68
vs. control 0.005¶ $80
ICER, incremental cost-effectiveness ratios; NHS, National Health Se
* Costs reported in US dollars at 2008 prices.
† Relative to comparator treatments (usual care, education, etc.).
‡ Total QALYs were reported as incremental difference.
§ Calculated by review authors by using reported per session cost of
 ICER was adjusted for baseline costs/covariates.
¶ Calculated by review authors by using area under the curve accounQALY gains resulted in an estimated cost of $538,750 per QALY.This estimate is not considered to be cost-effective based on con-
ventional standards of cost-effectiveness. No improvement in
WOMAC scores was found.
The second study evaluated a six-session self-management pro-
gram in addition to the provision of an education booklet [33]. The
self-management program focused on principles of self-help, emo-
tion management, exercise instruction, disease education, commu-
nication skills, painmanagement, and healthy eating. From the per-
spective of the NHS and social services sector and relative to the
provision of an education booklet alone, the program cost more and
resulted in aQALY loss of 0.01 (95%CI –0.04 to 0.01). Fromthe societal
perspective, theQALY losswas offset by slightly lower programcosts
($44 savings). Neither estimate is considered cost-effective based on
conventional standards of cost-effectiveness. No significant im-
provement in HRQoL was found by using the SF-36.
The third study evaluated a program of exercise and diet rela-
tive to diet alone, exercise alone, and a healthy lifestyle control
ean program
st per person*
Incremental cost per QALY*,† Primary analysis
perspective
ot reported Cost saving (no point estimate
reported)
NHS and social services
sector
$830 Cost saving Societal
$452 NA Health-care funder
NA
NA
$190–$480§ $25,707* per QALY gained Societal
ot reported $63,019 saved per QALY lost
(95% CI –$128,374 to
$2,040,599)
Societal
ot reported Dominated by usual care NHS and social services
sector
$454 Dominated by usual care
$522 Dominated by usual care
$103 Cost saving (no point estimate
reported)
Not reported
$211
$255 $538,750 per QALY gained Social direct cost
$6,126 NA Health-care funder
$2,960 NA
$2,828 NA
$192 NA
$273 Dominated by control/ NHS and social services
sector/societal
$4400 saved per QALY lost
ot reported Not available (insufficient
data)
Not reported
NA, not applicable; QALY; quality-adjusted life-year.
o $32 for 10 to 15 sessions.
for baseline with published data.t M
co
N
N
N
N
rvice;
$19 t[35]. From the perspective of the health-care funder, the diet and
Table 3 – Risk of bias assessment for health outcomes.
Risk of bias assessment* Cochrane
[28]
Coupe [13] Hurley [29] Jessep
[32]
Lord [30] Nunez [37] Patel [33] Reinhold [36] Richardson [19,31] Sevick [34] Sevick [35]
Was the method of randomization
adequate?
Yes Yes Yes Yes Don’t know Yes Yes Yes Yes Yes Yes
Was treatment allocation
concealed?
No Don’t know Yes Yes Don’t know Don’t know Yes Yes Yes Yes Yes
Were groups similar at baseline
regarding most important
prognostic indicators?
Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
Was the patient blinded to
intervention?
No No No No No No No No No No No
Was the care provider blinded to
intervention?
No No No No No No No No No No No
Was the outcome assessor blinded
to intervention?
No No No No No No No No No No No
Were cointerventions avoided or
similar?
No Don’t know Don’t know Yes Don’t know No Yes Yes Yes Don’t know Don’t know
Was compliance acceptable in all
groups?
Yes Yes Yes Yes Yes Don’t know Yes Don’t know Yes Yes Yes
Was the dropout rate described
and acceptable?
No Yes Yes Yes Yes Yes Yes No No Yes Yes
Was the timing of the outcome
assessment in all groups
similar?
Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes
Did the analysis include an
intention to treat analysis?
Yes Yes Yes Yes Yes No Yes No Yes Yes Yes
Risk of bias High Low Low Low High High Low High Low Low Low
* Operationalization of the risk of bias criteria listed can be found in the article by van Tulder et al. [23].
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9V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 – 1 2exercise intervention cost more than did the other three interven-
tions and produced a greater benefit on all subscales of the
WOMAC. The diet and exercise intervention was found to be sig-
nificantly more effective than the health lifestyle control by using
the WOMAC pain and function subscales, 30.3% (P  0.05) and
4.3% (P  0.01), respectively. An improvement was also found on
he stiffness subscale of the WOMAC, but it was not significant.
ALYs were not reported, and we were unable to calculate them
rom the published data.
The fourth study evaluated a therapeutic education and func-
ional readaptation program led by a health educator that included
nergy conservation and joint protection strategies, pain control, use
f assistive devices, exercise instruction, and pain medication pre-
cription [37]. Although the studywas not a full economic evaluation
nd cost-effectiveness was not addressed, general practitioner costs
ere reported. Relative to an alternative treatment regimen of two
eneral practitioner visits and pain medication, the therapeutic ed-
cation and functional readaptation program resulted in a $12 de-
rease in costs, an incremental QALY gain of 0.04, and an improve-
ent of 5.63 points (95%CI 0.48–10.78; P 0.035) inWOMAC function
core at 9months. Also, the number of analgesics taken per week by
articipants in the therapeutic education and functional readapta-
ion program increased significantly (P 0.036).
Further information about the characteristics of the included
tudies and the key results of the cost-utility analyses are reported
n Tables 1 and 2, respectively.
Methodological quality of trials
We considered the methodological quality of the RCTs to be an
important underlying determinant of the quality of the economic
evaluations (Table 3). Seven studies satisfied at least six items on
the risk-of-bias checklist, indicating low risk of bias [13,29,31-35].
In most studies, assessors were reported to be blind to group alloca-
tion. Nevertheless, in all studies participantswere not blind to group
allocation and used self-reported outcome measures; therefore, as-
sessor blinding was scored as unmet for all studies (Table 3).
Quality of economic analyses
Eight studies [13,28–31,33,35,36] met the 75-point threshold de-
arcating “low”-quality studies from “high”-quality ones (Table
). For eight studies [13,28,30–35], their time horizons for costs and
ealth outcomeswere considered for at least 1 year. For the remain-
ng three studies [29,36,37], their time horizons were 6, 3, and 9
onths, respectively. None of the 11 studies considered costs and
ffects in the longer term such as over the participants’ lifetimes.
The studies’ intervention comparators were diverse. They in-
luded usual care [28–30], a home exercise program [31], a patient
education program [34], delayed acupuncture [36], the Dutch
physiotherapy guidelines [13], two general practitioner visits, pre-
cribed pain medication [37], an education booklet [33], usual
hysiotherapy [32], and a healthy lifestyle intervention [35].
All but one [35] of the studies meeting the 75-point quality
hreshold addressed sample uncertainty via bootstrapping [13,28–
1,36]. Of these studies, seven performed sensitivity analyses
13,29–31,33,35, 36]. In addition, just over half of the studies ad-
ressed decision uncertainty by providing cost-effectiveness ac-
eptability curves [28,29,31,33,36]. Of the two economic studies
hat did not meet the quality threshold, one performed a sensitiv-
ty analysis but did not address sampling uncertainty [34] and the
ther addressed neither source of uncertainty [32].
Discussion
Despite recommendations for nonpharmacologic, nonsurgical in-
terventions in OA management guidelines, there is limited evi-
dence that such interventions are cost-effective. We could findonly 11 published studies that included evidence of this type.
Moreover, just 5 of these 11 studies exceeded the quality threshold
for the QHES and were associated with RCTs with a low risk of
methodological bias. We created the QHES guide (see Appendix 2
in Supplemental Materials at doi: 10.1016/j.jval.2011.09.003) to
make our grading decisions about the quality of these studies
transparent. We also reported the characteristics of the studies in
detail (Table 1) so that readers would be able to judge for them-
selves the extent to which particular studies are relevant and gen-
eralizable to their own patients or population groups.
The evaluation of an intervention’s cost-effectiveness is espe-
cially sensitive to the particular comparator used. It is important
that usual care or an existing treatment of known cost-effective-
ness is the comparator so that the study is able to address the
fundamental issue of whether the new treatment improves the
overall efficiency of health-care spending for the disease or popu-
lation under investigation [39]. Unfortunately, more than half of
the studies in our review included comparators of unknown cost-
effectiveness. Therefore, the capacity of these studies to address
the above-mentioned fundamental issue is seriously compro-
mised. Only three studies identified usual care as the comparator
[28–30], and two others [31,33] used the equivalent of a “do-noth-
ng” comparator when evaluating a home-based exercise program
nd education booklet, respectively.
Health outcomes other than QALYs are often reported in eco-
omic evaluations, enabling decision-makers to consider trade-offs
etween a range of benefits. All but one of the RCTs [34] included the
OMAC scale as an outcome measure, but the economic studies
ither didnot report theWOMAC [30,31,33] or themanner inwhich it
was reported precluded comparisons of studies [13,28,29,32,36]. Only
one study [13] included the OMERACT-OARSI criteria, which has
been recommended as a clinical outcome measure for use in eco-
nomic evaluations of treatments for OA [40].
Two of the rehabilitation studies [13,29] and two of the lifestyle
tudies [33,35] had low risks of bias for both health and cost out-
comes. Three of these four studies produced smaller treatment
effects than did their comparators when QALYs were used as the
measure of benefit [13,29,33], and the fourth did not report QALYs
[35]. The probability that the ESCAPE-knee pain rehabilitation pro-
gram was cost-effective was just 38% when a WTP threshold of
$32,000 per QALYwas applied in the cost-effectiveness acceptabil-
ity curve [29]. The probability that the arthritis self-management
program was cost-effective peaked at 20% for WTP thresholds of
up to $46,000 per QALY [33].
The third study, assessing behavioral-graded activity, reported
both QALY losses and lower costs that translated to $63,000 saved
per QALY lost (2008 US dollars) [13]. In other words, for each QALY
lost by undertaking this intervention, $63,000 is saved that could,
potentially, be used for other health-care services or treatments.
The value that society is willing to accept (WTA) as compensation
for the loss of a QALY and the value that society is willing to pay to
gain a QALY are often regarded as being equal in order to simplify
the interpretation of the cost-effectiveness plane [41]. If the
threshold values of WTP and WTA are equal (i.e., the relationship
between WTP and WTA is symmetrical), the $63,000 saved by the
behavioral-graded activity program represents good value for
money as it exceeds $50,000. There is evidence, though, that WTA
threshold values are higher than WTP values, with the “selling
price” (WTA) of a QALY on average 1.9 times greater thanWTP val-
ues [41]. On this basis, the $50,000-WTP threshold per QALY corre-
sponds to a $95,000 WTA threshold, and the $63,000 per QALY, in
effect, “offered” by the behavioral-graded activity represents poor
value for money because it is below the $95,000 threshold.
The cost-effectiveness results of the two studies of water-
based exercise therapy and acupuncture, respectively [28,36], in-
dicated that they were good value for money. Our confidence in
these results, however, is undermined by the studies’ limitations.
10 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 – 1 2Table 4 – Quality of health economics studies assessment results.
Quality of Health Economics
Studies assessment
Points
available
Cochrane
[28]
Coupe
[13]
Hurley
[29]
Jessep
[32]
Lord
[30]
Nunez
[37]
Patel
[33]
Reinhold
[36]
Richardson
[19,31]
Sevick
[34]
Sevick
[35]
1. Was the study objective
presented in a clear, specific,
and measurable manner?
7 7 7 0 0 7 0 7 7 7 7 7
2. Were the perspective of the
analysis (societal, third-party
payer, etc.) and reasons for its
selection stated?
4 4 4 4 0 4 0 4 4 0 0 4
3. Were variable estimates used
in the analysis from the best
available source (i.e., RCT 
best, expert opinion  worst)?
8 0 8 8 8 0 0 8 0 8 8 8
4. If estimates came from a
subgroup analysis, were the
groups prespecified at the
beginning of the study?
1 1 0 1 1 1 1 1 0 1 1 1
5. Was uncertainty handled by
(1) statistical analysis to
address random events, (2)
sensitivity analysis to cover a
range of assumptions?
9 0 9 9 0 9 0 9 9 9 0 0
6. Was incremental analysis
performed between
alternatives for resources and
costs?
6 6 6 6 0 6 0 6 6 6 6 6
7. Was the methodology for data
abstraction (including the
value of health states and
other benefits) stated?
5 5 5 5 5 5 5 5 5 5 5 5
8. Did the analytic horizon allow
time for all relevant and
important outcomes? Were
benefits and costs that went
beyond 1 y discounted (3%–
5%) and justification given for
the discount rate?
7 7 7 0 7 7 0 7 0 7 7 7
9. Was the measurement of
costs appropriate and the
methodology for the
estimation of quantities and
unit costs clearly described?
8 8 8 8 0 8 0 8 8 8 8 0
10. Was the primary outcome
measure(s) for the economic
evaluation clearly stated and
were the major short-term,
long-term, and negative
outcomes included?
6 6 6 6 6 6 0 6 6 6 6 6
11. Were the health outcomes
measures/scales valid and
reliable? If previously tested
valid and reliable measures
were not available, was
justification given for the
measures/scales used?
7 7 7 7 7 7 7 7 7 7 0 7
12. Were the economic model
(including structure), study
methods and analysis, and
the components of the
numerator and denominator
displayed in a clear,
transparent manner?
8 0 8 8 8 8 0 8 8 8 8 0
13. Were the choice of economic
model, main assumptions,
and limitations of the study
stated and justified?
7 7 7 7 0 0 0 7 7 7 7 7
14. Did the author(s) explicitly
discuss the direction and
magnitude of potential
biases?
6 6 6 6 0 6 0 6 6 6 6 6(continued on next page)
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incremental cost-effectiveness ratio estimatesweremarred by the
lack of a sensitivity analysis [28] and an inadequate expression of
ample uncertainty [36]. In addition, the acupuncture study was
imited to a 3-month time horizon [36].
The study of class-based exercise exhibited low risks of bias for
oth health and cost outcomes and indicated good value for
oney as the intervention incurred lower health-care costs and
chieved more QALYs than did its comparator [19,31]. The proba-
ility of class-based exercise being good value for money given a
ecision-maker’s WTP of $17,000 per QALY was greater than 70%.
lthough providing 95% confidence limits is the norm when re-
orting measures of effect, it is debatable whether cost-effective-
ess results require a 95% level of confidence [42].
Limitations
Our review has several limitations. First, it is restricted to trial-
based economic studies of nonpharmacologic, nonsurgical treat-
ments of hip and/or knee OA, and therefore model-based eco-
nomic evaluations and evaluations of other technologies were not
included. Trial-based economic analyses and model-based analy-
ses are not considered comparable in a systematic review of eco-
nomic studies [43]. Therefore, in order to retain comparability,
only one form of economic analysis should be assessed in a sys-
tematic review. Second, just one author (D.P.) screened the search
results for review of full-text articles, though a second author
(M.C.R.) was consulted during the review of full-text articles before
the final inclusion or exclusion decision was reached for the arti-
cles. A third limitation of our review is the small number of studies
that met our inclusion criteria, which is somewhat surprising
given hip and knee OA’s large burden of disease and the call for
cost-effective treatments at the start of the Bone and Joint Decade
in the new millennium [44]. Fourth, the generalizability of our
study results is limited by the heterogeneity of the interventions
and comparators evaluated and the fact that relatively few studies
were available.
A controversy in the literature is the extent to which system-
atic reviews of economic studies are capable of providing general-
izable results given the studies’ heterogeneity [43]. Most of the
studies included in our review explicitly identified themselves as
being pragmatic trials (Table 1), which is commendable as this
type of trial is generally regarded as the preferred approach for
trial-based economic evaluations [45]. Pragmatic trials, however,
by their nature, include real-world idiosyncrasies peculiar to the
particular environment in which the trial was undertaken, so that
comparing trials vis-à-vis each other can be problematic [43]. In
favoring external validity, pragmatic trials inevitably sacrifice in-
ternal validity and hence strict comparability or repeatability. On
the other hand, explanatory trials pursuing results that are “meth-
odologically pure” increase the risk that outcomes are clinically
meaningless [46]. In recognition of these important trade-offs, a
balance between internal and external validity is required [47].
Table 4 (continued)
Quality of Health Economics
Studies assessment
Points
available
Cochrane
[28]
Coupe
[13]
Hurl
[29
15. Were the conclusions/
recommendations of the
study justified and based on
the study results?
8 8 8 8
16. Was there a statement
disclosing the source of
funding for the study?
3 3 3 3
Total score 100 75 99 86
RCT, randomized controlled trial.In our review we sought to acknowledge these trade-offs byhighlighting each study’s risk of bias with respect to internal va-
lidity aswell as assessing the quality of the economic analysis. The
internal validity criteria (Table 3) specifically address attrition bias
and the use of cointerventions, which allows readers to judge
whether contamination or dilution of the treatment effect may
have occurred. We responded to the studies’ complexity by high-
lighting the conservative treatment with the most support based
on high internal validity and a high-quality economic analysis
instead of attempting to report an average result [43]. In our opin-
ion, a worthwhile area for future research is the development of
assessment tools that identify and balance the biases related to
both internal validity and external validity. In addition, we believe
a discourse is needed to consider how to make decisions about
interventions that are difficult to compare.
Recommendations for future research
We have five main recommendations. First, outcomes should be
more uniformly reported to enable comparisonwith other studies.
We recommend that trials regularly collect HRQoL data by using
common generic instruments for calculating QALYs. Future eco-
nomic analyses based on trials that measure the WOMAC should
not selectively report on one of the WOMAC subscales, but rather
should report the WOMAC index score that incorporates all three
subscales. Echoing Drummond et al. [39,40], we also recommend
that future studies use usual care, the equivalent of a “do-nothing”
alternative, or justify the cost-effectiveness of their comparator
and that the analytic horizon of economic evaluations of symp-
tom-modifying treatments of OA be at least 1 year. To improve
reporting of threats to internal validity, we recommend that re-
searchers report levels of adherence and use of cointerventions in
economic studies. Finally, on the basis of this review overall, we
recommend that more cost-effectiveness studies with highmeth-
odological standards and common clinical outcomes be con-
ducted to better inform clinicians, funders, and policy makers.
Conclusion
Most of the RCTs in our review exhibited high risks of bias for the
cost and/or effect components of their cost-effectiveness esti-
mates. Current guidelines recommend exercise and patient edu-
cation for patients with hip and/or knee OA, but evidence of the
cost-effectiveness of these conservative treatments is limited.
Consistent measures of potential biases impacting on internal va-
lidity and external validity are needed so that the information
from systematic reviews of economic evaluations is more useful
for decision makers. When QALYs are used as the measure of
benefit, exercise programs appear to offer the best value for
money for the conservative management of hip and/or knee OA.
Source of financial support: This research was supported in
part by a contract from the Health Research Council of New Zea-
land and by the School of Physiotherapy, University of Otago, Dun-
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Lord
[30]
Nunez
[37]
Patel
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